A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1446-1449

  Kelton, J G ^a   Warkentin, T E ^a   Moore, J C ^a   Arnold, D M ^a   Nazi, I ^a   Arepally, G M ^b   Roach, J M ^c   Fier, I ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Momenta Pharmaceutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOMIPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; ANTIBODY PRODUCTION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME IMMUNOASSAY; FALSE NEGATIVE RESULT; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFORMED CONSENT; INNATE IMMUNITY; LETTER; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT;

AUTOANTIBODIES; HEPARIN; HUMANS; MALE; PLATELET FACTOR 4; PROSPECTIVE STUDIES;

EID: 84863441210     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04759.x     Document Type: Letter

References (10)

1. Amiral J, Bridey F, Dretfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
2. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 161-7.
3. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2607-15.
4. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-9.
5. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341-6.
6. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
7. Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Junger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-803.
8. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
9. Warkentin TE, Sheppard JI, Moore JC, Sigoiun CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-detependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-12.
10. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010; 116: 1761-6.